Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. | |
| BSE Limited | "Exchange Plaza" | |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |
| Mumbai - 400 001 | Mumbai - 400 051 | |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ | |
| 22722037 / 22722039 | 26598238 |
Promius Pharma LLC, a wholly-owned subsidiary
of the Company, today confirmed that it has filed a lawsuit for patent infringement in the United States District Court for Eastern
District of Texas against Perrigo UK FINCO Limited Partnership, Perrigo Israel Pharmaceuticals Ltd., and Taro Pharmaceuticals,
Inc. in response to two paragraph-IV notice letters received for its twice daily topical spray SERNIVO (betamethasone dipropionate,
0.05%) product. Promius anticipates this lawsuit will trigger a 30 month stay of FDA approval of Perrigo's and Taro's
SERNIVO spray, 0.05% is protected by six
Orange Book patents that expire in 2030. Promius will continue to vigorously defend its SERNIVO intellectual property rights
against infringement wherever they are challenged.
This is for your information.
| With regards, | |
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)